clinical trial · NCT06533553
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
Areteia Therapeutics·phase2·active not recruiting·n = 30
Chronic Obstructive Pulmonary DiseaseDexpramipexole Dihydrochloride
brief summary
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
started
Jul 9, 2024
primary completion
Oct 1, 2025
completion
Dec 1, 2025
last updated
May 14, 2025
official title
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol